Blume-Jensen Peter 4
4 · Acrivon Therapeutics, Inc. · Filed Nov 18, 2025
Insider Transaction Report
Form 4
Blume-Jensen Peter
DirectorPresident and CEO
Transactions
- Tax Payment
Common Stock
2025-11-14$2.24/sh−490$1,098→ 314,706 total(indirect: See Footnote) - Tax Payment
Common Stock
2025-11-14$2.24/sh−59,765$133,874→ 2,066,675 total
Footnotes (3)
- [F1]Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
- [F2]These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
- [F3]These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.